Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Core Insights - Arvinas, Inc. announced the acceptance of two abstracts for presentation at the 2024 American Society of Clinical Oncology Annual Congress, focusing on ARV-766 for prostate cancer and TACTIVE-K for breast cancer treatment [1][2] Group 1: Presentation Details - The first presentation is titled "ARV-766, a PROteolysis TArgeting Chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): initial results of a phase 1/2 study," scheduled for June 3, 2024 [2] - The second presentation is titled "TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/HER2- advanced breast cancer," scheduled for June 2, 2024 [2] Group 2: Product Information - ARV-766 is an investigational PROTAC protein degrader targeting the androgen receptor, showing preclinical activity against both wild type and mutated AR tumors, which are common in resistance to current therapies [3] - Vepdegestrant is an investigational PROTAC protein degrader targeting the estrogen receptor for ER+/HER2- breast cancer, developed in collaboration with Pfizer, and has received Fast Track designation from the FDA [4] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins using its proprietary PROTAC® Discovery Engine platform [5] - The company has four clinical-stage programs, including vepdegestrant and ARV-766, targeting various cancers and neurodegenerative disorders [6]